GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
90.29
+2.88 (3.29%)
At close: Aug 26, 2026, 4:00 PM EDT
90.26
-0.02 (-0.03%)
Pre-market: Aug 27, 2026, 9:09 AM EDT
GeneDx Holdings Revenue
GeneDx Holdings had revenue of $114.44M in the quarter ending June 30, 2026, with 11.44% growth. This brings the company's revenue in the last twelve months to $454.43M, up 25.42% year-over-year. In the year 2025, GeneDx Holdings had annual revenue of $427.54M with 39.97% growth.
Revenue (ttm)
$454.43M
Revenue Growth
+25.42%
P/S Ratio
5.93
Revenue / Employee
$349,558
Employees
1,300
Market Cap
2.69B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 427.54M | 122.09M | 39.97% |
| Dec 31, 2024 | 305.45M | 102.88M | 50.79% |
| Dec 31, 2023 | 202.57M | -32.13M | -13.69% |
| Dec 31, 2022 | 234.69M | 22.50M | 10.60% |
| Dec 31, 2021 | 212.20M | 32.87M | 18.33% |
| Dec 31, 2020 | 179.32M | -16.85M | -8.59% |
| Dec 31, 2019 | 196.17M | 62.83M | 47.12% |
| Dec 31, 2018 | 133.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.27B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
| BillionToOne | 397.41M |
| Adaptive Biotechnologies | 308.08M |
WGS News
- 3 days ago - GeneDx announces data published in Genetics in Medicine on genome sequencing - TheFly
- 3 days ago - GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's - Business Wire
- 15 days ago - GeneDx Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 16 days ago - GeneDx launches new online offering to expand accessibility of exome testing - TheFly
- 16 days ago - GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy - Business Wire
- 20 days ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire
- 23 days ago - GeneDx price target raised to $90 from $75 at Canaccord - TheFly
- 23 days ago - GeneDx Holdings Earnings Call Transcript: Q2 2026 - Transcripts